Ravi Kalyanaraman
About Ravi Kalyanaraman
Ravi Kalyanaraman is the Director at Bristol-Myers Squibb in New Brunswick, New Jersey, with over 20 years of experience in the pharmaceutical industry, specializing in drug discovery and development.
Current Position at Bristol-Myers Squibb
Ravi Kalyanaraman currently holds the position of Director at Bristol-Myers Squibb in New Brunswick, New Jersey, United States. In this role, he utilizes his extensive expertise in drug discovery and development to lead various initiatives. His responsibilities include overseeing scientific projects, mentoring junior scientists, and collaborating with cross-functional teams to ensure the success of multiple programs.
Previous Roles at Bristol-Myers Squibb
Ravi Kalyanaraman has a long history at Bristol-Myers Squibb, spanning from 2002 to 2018. During these 16 years, he progressed through several roles including Scientist, Senior Scientist, and Associate Director. In these positions, he was instrumental in contributing to multiple successful drug patents and driving innovations in medicinal and organic chemistry.
Earlier Career Experience
Prior to his tenure at Bristol-Myers Squibb, Ravi Kalyanaraman worked at Sidmak Laboratories/Pliva Pharmaceuticals as a Senior Chemist from 2001 to 2002. Before that, he served as an Assistant and Associate Professor at Bemidji State University from 1997 to 2001, where he mentored students and conducted significant research. Ravi's early post-doctoral experience was at the University of Puerto Rico from 1995 to 1997.
Educational Background
Ravi Kalyanaraman earned his PhD in Chemistry from the University of Idaho, where he studied from 1990 to 1995. He also holds a Master of Science degree from the University of Madras, completed between 1986 and 1989, and a Bachelor of Science degree from Presidency College, where he studied from 1983 to 1986. His foundational education was completed at PS High School in Mylapore.
Research and Publications
Ravi Kalyanaraman has published numerous research papers in peer-reviewed journals, demonstrating his expertise in organic and medicinal chemistry. His work has gained recognition for its impact on scientific research and innovation, and he is frequently invited to speak at international conferences. His research contributions have significantly advanced the field of drug discovery and development.